Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Moleculin Biotech announced results from an independent market assessment showing strong physician interest in its lead asset Annamycin for relapsed/refractory AML. Oncologists reported an average likelihood-to-prescribe score of 6 out of 7, citing deep remissions, transplant-bridging potential, and reduced cardiotoxicity as key drivers. Payers also indicated strong support for Annamycin’s value proposition, driven by its efficacy, safety profile, and broad applicability to patients without actionable mutations.
Key figures
- Drug Name
- Annamycin (naxtarubicin)
- Phase Of Trial
- Phase 2b/3
- Likelihood to prescribe score
- 6 out of 7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.